The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement

• Status: Completed
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators research the early improvement of fluid retention and mid-term prognosis through the administration of tolvaptan for the patient with tricuspid regurgitation and right heart failure after left heart valves replacement.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Chest Hospital
• Treatments: Tolvaptan; Torsemide

Criteria

Inclusion Criteria:

1. Patient with tricuspid regurgitation and right heart failure after left heart valves replacement

2. Patients who takes existing diuretic

3. The patient is willing to participate in the study

Exclusion Criteria:

1. Patients with hypersensitivity to study drug

2. Anuric patients

3. Patients with hypernatremia

4. Female patients who are pregnant, possibly pregnant, or lactating, or who plan to become pregnant

5. Malignant tumor

6. Patients with serious hepatic disorder or Serious Renal failure

7. Patients otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the study